Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sublingual misoprostol and postpartum hemorrhage
PACTR202504725860997Phase 4Not yet recruiting
- Sponsor
- Dr. Okoiseh
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of misoprostol and oxytocin in postpartum hemorrhage (PPH) (2 arms), sponsored by Dr. Okoiseh. Primary endpoint: Incidence of primary postpartum hemorrhage. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
misoprostoloxytocin
03
Conditions
postpartum hemorrhage (PPH)
Beyond the preview
Go deeper on PACTR202504725860997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504725860997.